COLUMBUS, OHIO ? Which would you choose?

Four or more insulin shots every day? Or one shot a day, followed by a deep breath before each meal?

It’s a choice some diabetics will get to make come September, when a new, inhaled form of insulin, Exubera, hits the market.

Exubera, approved by the U.S. Food and Drug Administration in January, is expected to find its way into pharmacies by September.

Since insulin therapy began in the 1920s, diabetics have had little choice – pills or injections. That choice was determined more by the severity of their conditions than their preferences.

Exubera, though, comes in powdered form and is inhaled through a tube-like device.

Pfizer is the first to get inhaled insulin to the market, but at least eight other drug companies are testing inhaled insulin in clinical trials, according to the Pharmaceutical Research and Manufacturers of America (PhRMA).